Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in T-ALL and T-Lymphoblastic Lymphomas
NCT00199030Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Feb 2004
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in t-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), sponsored by Goethe University Frankfurt. Started Feb 2004; status: completed.
02
Drugs
alemtuzumab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00199030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199030.